On October 9, Goldman Sachs released a research report, giving CSPC Pharma a target price of 10.03 Hong Kong dollars based on the Sum of the Parts valuation method (SOTP), reflecting a 40.9% upside potential, with a 'buy' rating. The report mentioned that CSPC Pharma announced plans to grant global rights to YS2302018 (a preclinical stage lipoprotein(a) small molecule inhibitor) and any products containing YS2302018. The company's first collaboration with AstraZeneca is seen by the bank as an important step in the company's global expansion process. The company aims to complete 1-2 BD transactions by 2024, emphasizing the continuous review of its product line, strengthening business expansion efforts, with the bank expecting more transactions to occur in the future.
大行评级｜高盛：予石药集团“买入”评级 与阿斯利康交易是全球扩张的重要一步
Goldman Sachs: Buy rating on cspc pharma, the trade with astrazeneca is an important step in global expansion.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated